Quarterly ResultMay 13, 2026, 04:28 PM
Vivani Medical Q1 Net Loss $(6.78)M; Raises $9.71M in Financing
AI Summary
Vivani Medical, Inc. reported a net loss of $(6.78) million for the first quarter of 2026, an increase from $(6.30) million in the prior year period. However, net loss per common share improved to $(0.08) from $(0.11) due to increased shares outstanding. The company significantly bolstered its liquidity by raising $9.71 million through various financing activities, including private sales and a registered direct offering. Despite these capital infusions, Vivani Medical continues to operate on a going concern basis, projecting its current cash to last through the second quarter of 2027 and emphasizing the need for additional funding thereafter.
Key Highlights
- Net loss for Q1 2026 was $(6.78) million, compared to $(6.30) million in Q1 2025.
- Net loss per common share was $(0.08) in Q1 2026, an improvement from $(0.11) in Q1 2025.
- Total operating expenses increased to $6.82 million in Q1 2026 from $6.56 million in Q1 2025.
- Cash and cash equivalents were $19.75 million as of March 31, 2026, up from $16.23 million.
- Net cash provided by financing activities totaled $9.71 million in Q1 2026.
- This financing included $5.65 million from 2025 Private Sales and $4.17 million from 2026 offerings.
- Company estimates cash sufficient through Q2 2027, requiring more capital thereafter.